22 research outputs found
Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain
Direct cost; Family impact; Juvenile arthritisCost directe; Impacte familiar; Artritis juvenilCoste directo; Impacto familiar; Artritis juvenilBackground: Juvenile idiopathic arthritis (JIA) is the most frequent chronic rheumatic disease in children. If inflammation is not adequately treated, joint damage, long-term disability, and active disease during adulthood can occur. Identifying and implementing early and adequate therapy are critical for improving clinical outcomes. The burden of JIA on affected children, their families, and the healthcare system in Spain has not been adequately assessed. The greatest contribution to direct costs is medication, but other expenses contribute to the consumption of resources, negatively impacting healthcare cost and the economic conditions of affected families.
Objective: To assess the direct healthcare, indirect resource utilization, and associated cost of moderate-to-severe JIA in children in routine clinical practice in Spain.
Methods: Children were enrolled in this 24-month observational, multicentric, cross-sectional, retrospective study (N = 107) if they had been treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs), had participated in a previous study (ITACA), and continued to be followed up at pediatric rheumatology units at 3 tertiary Spanish hospitals. Direct costs included medication, specialist and primary care visits, hospitalizations, emergency visits or consultations, surgeries, physiotherapy, and tests. Indirect costs included hospital travel expenses and loss of caregiver working hours. Unitary costs were obtained from official sources (€, 2020).
Results: Overall, children had inactive disease/low disease activity according to JADAS-71 score and very low functional disability as measured by Childhood Health Assessment Questionnaire score. Up to 94.4% of children received treatment, mainly with bDMARDs as monotherapy (84.5%). Among anti-TNFα treatments, adalimumab (47.4%) and etanercept (40.2%) were used in similar proportions. Annual mean (SD) total JIA cost was €7516.40 (€5627.30). Average cost of pharmacological treatment was €3021.80 (€3956.20), mainly due to biologic therapy €2789.00 (€3399.80). Direct annual cost (excluding treatments) was €3654.60 (€3899.00). Indirect JIA cost per family was €747.20 (€1452.80).
Conclusion: JIA causes significant costs to the Spanish healthcare system and affected families. Public costs are partly due to the high cost of biologic treatments, which nevertheless remain an effective long-term treatment, maintaining inactive disease/low disease activity state; a very low functional disability score; and a good quality of life
A child with resistant Kawasaki disease successfully treated with anakinra: a case report
Background: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA). The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids, interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative. Case presentation: We present a 3 year-old Caucasian patient with KD without cardiac complications but with important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an effective treatment. Conclusions: To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an effective treatment option for other cases of resistant Kawasaki disease
Kawasaki disease is more prevalent in rural areas of Catalonia (Spain)
INTRODUCTION: Kawasaki disease (KD) is an acute self-limited
systemic vasculitis relatively common in childhood. The etiology
of KD is still unknown, although clinical, laboratory and
epidemiological features suggest an infectious origin or
trigger. Differences on incidence between countries have been
related to specific genetic factors, ethnicity, country of birth
and some other sociocultural and environmental factors. We
present a population-based study on incidence of KD in Catalonia
(Spain), focusing on differences between patients in rural and
non-rural areas of the region. METHODS: Observational
population-based study including all Pediatric Units in Catalan
hospitals, between 2004 and 2014. A 12-month (March 2013-March
2014) prospective collection of new cases of KD was carried out
to determine the incidence of KD. The rest of the data was
retrieved retrospectively. RESULTS: Data from 399 patients over
the 10-year study period was analyzed. Among the total KD
patients, 353 (88.5%) lived in non-rural areas and 46 (11.5%) in
rural areas. It was found that there is a significant difference
(P<.001) between the percentage of rural population observed
in patients with KD (11.5%), and the expected 5% of the Catalan
population. CONCLUSION: This is the first population-based study
showing significant differences on KD incidence rates between
rural and non-rural areas
Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group
Background: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology affecting mainly children less than 5 years of age. Risk factors for cardiac involvement and resistance to treatment are insufficiently studied in non-Japanese children. Objective: This study aimed to investigate the epidemiology, clinical features and risk factors for resistance to treatment and coronary artery lesions (CAL) in KD in Spain. Methods: Retrospective study (May 2011-June 2016) of all patients less than 16 years of age diagnosed with KD included in KAWA-RACE network (84 Spanish hospitals). Results: A total of 625 cases were analyzed, 63% were males, 79% under 5 year-olds and 16.8% younger than 12 months. On echocardiographic examination CAL were the most frequent findings (23%) being ectasia the most common (12%). Coronary aneurysms were diagnosed in 9.6%, reaching 20% in infants under 12 months (p 900,000 cells/mm3, maximum temperature 10 days and fever before treatment ≥ 8 days as independent risk factors for developing coronary aneurysms. Conclusions: In our population, children under 12 months develop coronary aneurysms more frequently and children with KD with anemia and leukocytosis have high risk of cardiac involvement. Adding steroids early should be considered in those patients, especially if the treatment is not started before 8 days of fever. A score applicable to non-Japanese children able to predict the risk of aneurysm development and IVIG resistance is necessary
Prevalence and Clinical Characteristics of SARS-CoV-2 Confirmed and Negative Kawasaki Disease Patients During the Pandemic in Spain
Introduction: COVID-19 has a less severe course in children. In April 2020, some children presented with signs of multisystem inflammation with clinical signs overlapping with Kawasaki disease (KD), most of them requiring admission to the pediatric intensive care unit (PICU). This study aimed to describe the prevalence and clinical characteristics of KD SARS-CoV-2 confirmed and negative patients during the pandemic in Spain. Material and Methods: Medical data of KD patients from January 1, 2018 until May 30, 2020 was collected from the KAWA-RACE study group. We compared the KD cases diagnosed during the COVID-19 period (March 1-May 30, 2020) that were either SARS-CoV-2 confirmed (CoV+) or negative (CoV-) to those from the same period during 2018 and 2019 (PreCoV). Results: One hundred and twenty-four cases were collected. There was a significant increase in cases and PICU admissions in 2020 (P-trend = 0.001 and 0.0004, respectively). CoV+ patients were significantly older (7.5 vs. 2.5 yr) and mainly non-Caucasian (64 vs. 29%), had incomplete KD presentation (73 vs. 32%), lower leucocyte (9.5 vs. 15.5 × 109) and platelet count (174 vs. 423 × 109/L), higher inflammatory markers (C-Reactive Protein 18.5vs. 10.9 mg/dl) and terminal segment of the natriuretic atrial peptide (4,766 vs. 505 pg/ml), less aneurysm development (3.8 vs. 11.1%), and more myocardial dysfunction (30.8 vs. 1.6%) than PreCoV patients. Respiratory symptoms were not increased during the COVID-19 period. Conclusion: The KD CoV+ patients mostly meet pediatric inflammatory multisystem syndrome temporally associated with COVID-19/multisystem inflammatory syndrome in children criteria. Whether this is a novel entity or the same disease on different ends of the spectrum is yet to be clarified
Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study
Background: Adult patients receiving anti-TNFα drugs are at increased risk of tuberculosis (TB), but studies in pediatric populations are limited, and the best strategy for latent tuberculosis infection (LTBI) screening in this population remains controversial. We describe the prevalence of LTBI prior to anti-TNFα therapy and the long-term follow-up after biological treatment initiation in a cohort of children and adolescents. Methods: Cohort observational study in children and adolescents receiving anti-TNFα agents in a tertiary-care pediatric hospital. LTBI was ruled out prior to the implementation of anti-TNFα drugs by tuberculin skin test (TST), and, from March 2012 on, QuantiFERON Gold-In Tube® test (QTF-G). During anti-TNFα treatment, patients were evaluated every 6 months for TB with history and physical examination. TST/QTF-G were not repeated unless signs or symptoms consistent with TB arose or there was proven TB contact. Results: The final cohort consisted of 221 patients (56.1 % female; 261 treatments), of whom 51.7 %/30.0 %/17.3 % were treated with etanercept/adalimumab/infliximab, respectively, for a variety of rheumatic diseases (75.6 %), inflammatory bowel disease (20.8 %), and inflammatory eye diseases (3.6 %). The median (IQR) age at diagnosis of the primary condition was 6.8 years (2.7-11.0) and the duration of the disease before implementing the anti-TNFα agent was 1.8 years (0.6-4.2). LTBI was diagnosed in 3 adolescent girls (prevalence rate: 1.4 %; 95 % CI: 0.4-4.2) affected with juvenile idiopathic arthritis: TST tested positive in only 1, while QTF-G was positive in all cases (including 2 patients already on etanercept). They all received antiTB chemoprophylaxis and were later (re)treated with etanercept for 24-29 months, without incidences. No incident cases of TB disease were observed during the follow-up period under anti-TNFα treatment of 641 patients-year, with a median (IQR) time per patient of 2.3 years (1.4-4.3). Conclusions: In our study, the prevalence of LTBI (1.4 %) was similar to that reported in population screening studies in Spain; no incident cases of TB disease were observed. In low-burden TB settings, initial screening for TB in children prior to anti-TNFα treatment should include both TST and an IGRA test, but systematic repetition of LTBI immunodiagnostic tests seems unnecessary in the absence of symptoms or known TB contact
Estudi d’incidència, prevalença i caracterÃstiques clÃniques de la malaltia de Kawasaki a Catalunya
[cat] ANTECEDENTS: La malaltia de Kawasaki (MK) és una vasculitis sistèmica autolimitada que afecta predominantment infants menors de 5 anys. L'etiologia de la MK és desconeguda i, malgrat que és més prevalent en països asià tics, especialment al Japó, amb una incidència anual que ha augmentat fins a 264.8 per 100,000 nens menors de 5 anys al 2012, té una distribució universal i es pot manifestar en qualsevol ètnia. La immunoglobulina intravenosa (IGIV) és un tractament efectiu i redueix la incidència de complicacions cardÃaques, tot i que existeixen pacients que no responen a aquest tractament. En població japonesa, s'han establert diferents escales per tal d'identificar aquests pacients amb risc de no resposta al tractament, una de les més utilitzades és l'escala d'Egami, tot i que la seva eficà cia no s'ha provat en població no japonesa. HIPÃ’TESI I OBJECTIUS: Aquest estudi ha estat dissenyat per a conèixer la incidència i les caracterÃstiques clÃniques de la MK a Catalunya. Aquestes s'assumeix que són similars a la d'altres països europeus i de la conca mediterrà nia per motius genètics i geogrà fics. També es pretén identificar variables clÃniques i/o biològiques pronòstiques que permetin classificar els pacients segons la gravetat, conèixer les caracterÃstiques clÃniques i epidemiològiques dels pacients diagnosticats de MK a Catalunya, identificar variables geogrà fiques i d'estacionalitat, identificar variables de resistència al tractament convencional de la MK i aplicar de l'escala d'Egami a la nostra població per tal de determinar si és efectiva en la prà ctica clÃnica dià ria. RESULTATS: Anà lisi de dades de 399 pacients entre 2004 i 2014. D'aquests, 233 (58.4%) presentaven MK complerta, 159 (39.8%) incomplerta i 7 (1.7%) van ser considerats pacients atÃpics. La incidència anual va ser de 8/100,000 en infants 8 anys al diagnòstic, la necessitat de més de 5 dies d’ingrés hospitalari, l’elevació de transaminases i la presència de piúria estèril, broncospasme, meningitis asèptica, dolor abdominal i uveïtis al diagnòstic van establir-se com a predictors de major risc d’aneurismes coronaris (p0.5 però no ho seria per a la detecció dels pacients de risc. . CONCLUSIONS: Aquest és el primer estudi poblacional sobre epidemiologia de la MK a Catalunya i l’à rea del Mediterrani Occidental. En general, la incidència, les caracterÃstiques clÃniques i els plans de tractament a la nostra cohort són similars a les descrites en altres països europeus. L’escala d’Egami presenta una baixa sensibilitat però una especificitat elevada en la població catalana i podria constituir-se, per tant, com una eina per a descartar aquells pacients amb baix risc de resistència al tractament.[eng] Background: Kawasaki disease (KD) is a self-limiting systemic vasculitis that predominantly affects children under 5 years. The etiology is unknown and, although it is more prevalent in Asian countries, especially Japan, it has a worldwide distribution. Intravenous immunoglobulin (IVIG) is an effective treatment and reduces the incidence of cardiac complications although there are patients who do not respond to this treatment. In Japanese population, different scores have been described to identify patients at risk of no response to conventional treatment; one of the most used is the Egami score, although its effectiveness has not been reproduced in non-Japanese population. Objectives: To determine the incidence and clinical features of KD in Catalonia. It is assumed that these are similar to that of other European countries and the Mediterranean basin due to genetic and geographical reasons. It is also intended to identify clinical variables or biological predictors to classify patients according to the severity, identifying geographic and seasonal patterns, identifying resistance variables to conventional treatment and applying Egami score to determine if it is effective in daily clinical practice in our population. Results: Data from 399 patients over the 10-year study period was analyzed (2004-2014). Of those, 233 (58.4%) had complete KD, 159 (39.8) incomplete KD and 7 (1.7%) were considered atypical KD. Mean annual incidence was 3.5/105 children 10th day of illness, ages 8yo and the presence of sterile piuria, broncospasm, aseptic meningitis, abdominal pain and uveitis at diagnosis were found to have higher risk of coronary aneurisms (CAA) (p0.5. CONCLUSIONS: This is the first population-based study on the epidemiology of KD in the Western Mediterranean area. Incidence, clinical features and treatment plans in our cohort are similar to those described in other European studies. Egami score has low sensitivity but high specificity in Catalan population and could be a tool to rule out patients at low risk of resistance to treatment
Usefulness of salivary cortisol as a marker of secondary adrenal insufficiency in paediatric patients
Background: The main cause of adrenal insufficiency (AI) in paediatric patients is prolonged treatment with corticosteroids. Determination of plasma cortisol (PC) during ACTH test is the most used adrenal function indicator in clinical practice. However, determination of salivary cortisol (SC), a simple test especially useful in children in order to avoid invasive procedures, can be used as an alternative technique for the diagnosis of adrenal disease.
Methods: A two-year prospective study (January 2014-January 2016) in paediatric patients (2-18 years of age) treated with corticosteroids for more than fifteen days, who were investigated for suspected AI. Low-dose ACTH test was used to determine adrenal function and samples for SC and PC were obtained simultaneously in basal situation and during the test (at 30, 60 and 90 minutes).
Results: 230 samples (118 PC-112 SC) of 30 studies belonging to 20 patients (4 males), mean age 10.93 years ± 3.69 SD. Pearson’s correlation coefficient showed a positive correlation between PC and SC (r = 0.618, p < 0.001). All the studies with some determination of PC higher than 18 μg/dL (n = 8) had a SC peak higher than 0.61 μg/dL with a specificity of 66.67% and a sensitivity of 93.94% (ROC analysis).
Conclusion: Measurement of SC is a less invasive, easier and quicker test than PC to measure plasma free cortisol levels. In our study, a SC peak in low-dose ACTH test higher than 0.61 μg/dL was able to discriminate patients without AI, and proved to be a useful tool in the initial evaluation of children with suspected AI.Introduction
The activation of the hypothalamic-pituitary-adrenal axis in response to critical illness and the resulting release of cortisol from the adrenal cortex are essential to stress adaptation. Adrenal insufficiency (AI) is described as the inability of adrenal glands to produce an appropriate hormonal secretion not only under stress but also in basal situation. Therefore, a low baseline plasma cortisol (PC) (< 5 μg/dL) and a poor cortisol response to stimulation with exogenous adrenocorticotropic hormone (peak < 18 μg/dL) are some of the defining criteria of this condition [1,2]. It is well known that the main cause of AI in paediatric patients is prolonged treatment with exogenous corticosteroids, which is an iatrogenic cause derived from the increasing complexity of paediatric pathologies and the increased use of prolonged high-dose corticosteroid therapy.
In clinical practice, adrenal function is usually assessed by the total PC (determined by low-dose ACTH test). This implies the placement of a vascular access which is often a traumatic experience for children.
PC includes protein-bound fraction and serum-free cortisol. The latter constitutes the biologically active form of the hormone and is responsible for glucocorticoid activity on peripheral organs. Most of the circulating cortisol is bound to plasma proteins (over 90%), such as cortisol-binding globulin (CBG) and albumin, whereas only about 10% of circulating cortisol is free. Hence, the measurement of plasma-free cortisol level has been considered more representative of adrenal function (especially in critically ill adults and children) [1,2], because some conditions, such as hypoalbuminaemia or hypoproteinaemia (frequent in critically ill patients or in patients with cirrhosis), may lead to misinterpretation of adrenal function with an overestimation of the prevalence of AI. But the direct measurement of free PC is a laboratory-dependent and time-consuming procedure that is not available for routine use. Salivary cortisol (SC) is one of the several indirect methods available to determine free PC [3], as SC levels accurately reflect free PC [4] even in cases of hypoalbuminaemia or CBG abnormality [1,5]. For this reason, in the last years, this technique (SC) has been introduced as a non-invasive tool in the diagnosis of adrenal cortical disorders, for its simplicity and applicability in the paediatric population. However, few studies to date have evaluated the usefulness of SC as a diagnostic method in children with AI. No interactions between exogenous corticoids and SC have been described [6].
The aim of the present study was to assess the usefulness of determining salivary cortisol levels as a diagnostic tool in children with suspected secondary iatrogenic AI.